MLICM
NVRO

Metropolitan Life Insurance Company (MetLife)’s NEVRO CORP. NVRO Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio NVRO Stock Details NVRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,902
Closed -$27.5K – 2208
2024
Q1 		$27.5K Sell
1,902
-390
-17% -$6.45K ﹤0.01% 1700
2023
Q4 		$49.3K Hold
2,292
– – ﹤0.01% 1454
2023
Q3 		$44.1K Buy
2,292
+331
+17% +$7.06K ﹤0.01% 1478
2023
Q2 		$49.8K Hold
1,961
– – ﹤0.01% 1414
2023
Q1 		$70.9K Sell
1,961
-161
-8% -$5.65K ﹤0.01% 1187
2022
Q4 		$84K Hold
2,122
– – ﹤0.01% 1152
2022
Q3 		$98.9K Hold
2,122
– – ﹤0.01% 1024
2022
Q2 		$93K Hold
2,122
– – ﹤0.01% 1093
2022
Q1 		$153K Sell
2,122
-7,000
-77% -$505K 0.01% 955
2021
Q4 		$740K Hold
9,122
– – 0.01% 1163
2021
Q3 		$1.06M Sell
9,122
-373
-4% -$48.8K 0.02% 907
2021
Q2 		$1.57M Buy
9,495
+212
+2% +$33.1K 0.02% 680
2021
Q1 		$1.29M Sell
9,283
-338
-4% -$55.2K 0.02% 771
2020
Q4 		$1.67M Sell
9,621
-91
-0.9% -$14.7K 0.02% 570
2020
Q3 		$1.35M Sell
9,712
-499
-5% -$66.7K 0.02% 592
2020
Q2 		$1.22M Buy
10,211
+1,208
+13% +$143K 0.02% 623
2020
Q1 		$900K Sell
9,003
-233
-3% -$28K 0.02% 736
2019
Q4 		$1.09M Sell
9,236
-415
-4% -$41.1K 0.02% 847
2019
Q3 		$830K Buy
9,651
+367
+4% +$27.8K 0.01% 965
2019
Q2 		$602K Hold
9,284
– – 0.01% 1185
2019
Q1 		$580K Hold
9,284
– – 0.01% 1202
2018
Q4 		$361K Hold
9,284
– – 0.01% 1418
2018
Q3 		$529K Hold
9,284
– – 0.01% 1322
2018
Q2 		$741K Buy
9,284
+183
+2% +$15.2K 0.01% 1074
2018
Q1 		$789K Buy
9,101
+28
+0.3% +$2.26K 0.01% 1013
2017
Q4 		$626K Sell
9,073
-12,425
-58% -$994K 0.01% 1133
2017
Q3 		$1.95M Buy
21,498
+2,604
+14% +$223K 0.01% 945
2017
Q2 		$1.41M Buy
18,894
+2,145
+13% +$172K 0.01% 1080
2017
Q1 		$1.57M Sell
16,749
-449
-3% -$40.7K 0.01% 1047
2016
Q4 		$1.25M Hold
17,198
– – 0.01% 1183
2016
Q3 		$1.79M Sell
17,198
-291
-2% -$26.3K 0.01% 992
2016
Q2 		$1.29M Buy
17,489
+5,374
+44% +$365K 0.01% 1117
2016
Q1 		$682K Buy
12,115
+240
+2% +$14.2K 0.01% 1393
2015
Q4 		$802K Buy
11,875
+830
+8% +$44.4K 0.01% 1304
2015
Q3 		$512K Buy
11,045
+313
+3% +$15.2K ﹤0.01% 1615
2015
Q2 		$577K Buy
+10,732
New +$547K ﹤0.01% 1650
2015
Q1 		– Sell
-8,465
Closed -$327K – 2466
2014
Q4 		$327K Buy
+8,465
New +$267K ﹤0.01% 2070

Other funds holding NVRO

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s NVRO Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of NEVRO CORP. (NVRO) in Q2 2024, closing a stake of 1,902 shares — an estimated $27.5K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in NVRO in Q4 2014 and held it in 37 quarters. The position peaked at $1.95M in Q3 2017. 152 funds tracked by Wall St. Rank hold NVRO as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining NEVRO CORP. position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,902 NEVRO CORP. shares in Q2 2024, an estimated $27.5K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in NEVRO CORP. in Q4 2014 and held it in 37 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s NEVRO CORP. position peaked at $1.95M in Q3 2017.
  • 152 funds tracked by Wall St. Rank held NEVRO CORP. as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.